<DOC>
	<DOCNO>NCT00257608</DOCNO>
	<brief_summary>This Phase IIIb , multicenter , randomize , placebo-controlled trial evaluate safety efficacy chemotherapy+bevacizumab follow bevacizumab+erlotinib versus bevacizumab+erlotinib placebo subject locally advanced metastatic NSCLC .</brief_summary>
	<brief_title>A Study Comparing Bevacizumab Therapy With Without Erlotinib First-Line Treatment Non-Small Cell Lung Cancer ( ATLAS )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed Informed Consent Form Histologically cytologically confirm NSCLC Advanced NSCLC recurrent disease INR great 1.3 aPTT great upper limit normal ( ULN ) within 28 day prior enrollment subject low molecular weight heparin fondaparinux . Subjects low molecular weight heparin fondaparinux require meet INR aPTT limit . Chronic fulldose anticoagulation warfarin permit . 18 year age old For woman childbearing potential sexually active men , use accept effective method contraception ( hormonal barrier method , abstinence ) prior enrollment duration study Prior systemic chemotherapy metastatic setting Treatment investigational market agent act either EGFR inhibition antiangiogenesis mechanisms Pregnancy lactation Any medical condition , include mental illness substance abuse , deem clinician likely interfere subject 's ability provide inform consent , cooperate , participate study , interfere interpretation result Active infection fever within 3 day enrollment Active malignancy lung cancer Radiation therapy site whole brain within 14 day prior enrollment History gross hemoptysis within 3 month prior enrollment Known hypersensitivity component cytotoxic chemotherapy combination , bevacizumab , tyrosine kinase inhibitor Inadequately control hypertension Unstable angina New York Heart Association Grade II great CHF Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior enrollment History myocardial infarction within 6 month prior enrollment History stroke within 6 month prior enrollment Symptomatic peripheral vascular disease within 6 month prior enrollment Evidence bleed diathesis coagulopathy Serious , nonhealing wound , ulcer , bone fracture Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior enrollment ; anticipation need major surgical procedure course study Current , recent , planned participation experimental drug study Genentechsponsored bevacizumab/erlotinib study Progressive neurologic symptom subject history brain metastasis History significant vascular disease ( e.g. , aortic aneurysm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>ATLAS</keyword>
	<keyword>Avastin</keyword>
	<keyword>Tarceva</keyword>
</DOC>